Loading manuals...

Humphrey FDT Perimeter Manual

Humphrey FDT Perimeter Manual Image

Detect vision loss from ocular diseases

Simple, Reliable, Proven

ocular diseases without specialized training

Humphrey FDT is produced by the leader in diagnostic equipment for eye disease – Carl Zeiss Meditec

The Humphrey FDT® is from Carl Zeiss Meditec, the world leader in diagnostic test equipment for ophthalmology. Carl Zeiss Meditec is also the developer and distributor of the Humphrey® Field Analyzer,  the recognized gold standard in visual field testing. Humphrey Field Analyzers are used by more eye care providers than any other automated diagnostic perimeter today.

Carl Zeiss Meditec, one of the world’s leading medical technology companies, offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. Diagnostic products range from slit lamps and fundus cameras to standard-setting diagnostic systems such as the Humphrey Field Analyzer, the Cirrus™ HD-OCT and the IOLMaster.® Carl Zeiss Meditec also produces surgical microscopes and innovative treatment systems for refractive laser surgery.

FDT can help your staff detect vision loss in

Clinically Validated
Multiple studies1-15 have shown that the Humphrey FDT detects visual field loss due to a variety of ocular diseases, including glaucoma. Thus FDT is ideal for clinics desiring to identify patients in need of ophthalmological referral.
• FDT is clinically validated in more than 170 peer-reviewed publications.

Proven Performance on Virtually all Patients
Studies have found that virtually all patients can  perform this fast and simple test with reliable results:
• Beijing Eye Study: 98% patient success
• Tajimi Population Screening Study: 98.7%  patient success.

The Humphrey FDT can detect visual field loss
associated with a variety of ocular diseases


Ocular diseases without specialized training

Use the FDT Anywhere:

  • General hospitals
  • Polyclinics
  • Community clinics
  • Industrial health check clinics
  • Optical shops

Patients with a positive FDT result can be referred for specialized ophthalmic examination. Interpretation criteria may be adjusted for local conditions.

Easy to Operate and Interpret
The FDT is optimized for use in non-ophthalmological settings and may be operated by healthcare workers having little or no specialty training in ophthalmology.

  • Simplified three touch operation
  • Patients may be tested using their own glasses
  • Short test: ~ 40 seconds per eye
  • Small footprint
  • Simplified interpretation of results

FDT is easy on patients

  • Comfortable headrest
  • Large, easily seen test stimuli
  • Ergonomic response button
  • Short testing time

The FDT is a small, automated peripheral vision testing device. The patient simply presses a response button whenever he/she sees a test stimulus. These simple  perating requirements, coupled with the instrument’s well-documented clinical performance, make it a natural choice to detect the effects of eye diseases on visual function.

FDT is ideal for screening

              • Highly sensitive in detecting visual field loss  associated with a range of eye diseases
              • Can be placed almost anywhere, including  non-ophthalmic clinical settings
              • Technician operated, with minimal training
              • Fast and easy testing for patients in 40 seconds per eye
              • Simple to understand test

 Shaded locations in the FDT printout indicate areas of visual field sensitivity that are outside normal limits.
• The results illustrated above are consistent with a  diagnosis of glaucoma. The darkest symbols indicate areas of the patient’s peripheral vision that were lower than that found in 99.5% of normal subjects.

The C-20-1 test emphasizes high specificity and is therefore best designed for general screening of  large populations. The C-20-5 test emphasizes high sensitivity to optimize detection of early, subtle  pathologic sensitivity loss, and is best designed for screening ophthalmic patients with risk factors or symptoms associated with eye diseases.

Humphrey FDT Perimeter

Selected References

  1. Johnson CA, Samuels SJ. Screening for glaucomatous visual field loss with frequency-doubling perimetry. Invest Ophthalmol Vis Sci. 1997 Feb; 38(2): 413-425.
  2. Parikh R, Naik M, Mathai A, et al. Role of frequency doubling technology perimetry in screening of diabetic retinopathy. Indian J Ophthalmol. 2006 Mar; 54(1): 17-22.
  3. Realini T, Lai MQ, Barber L. Impact of diabetes on glaucoma screening using frequency-doubling perimetry. Ophthalmology. 2004 Nov; 111(11): 2133-6.
  4. Thomas D, Thomas R, Muliyil JP, et al. Role of frequency doubling perimetry in detecting neuro-ophthalmic visual field defects. Am. J Ophthalmol; 2001 June; 131(6): 734-41.
  5. Wall M, Neahring RK, Woodward KR. Sensitivity and specificity of frequency doubling perimetry in neuro-ophthalmic disorders: a comparison with  conventional automated perimetry. Invest Ophthalmol Vis Sci. 2002 Apr; 43(4): 1277-83.
  6. Detry-Morel M, Zeyen T, et al; Belgian Glaucoma Society. Screening for glaucoma in a general population with the non-mydriatic fundus camera and the frequency doubling perimeter. Eur J Ophthalmol. 2004 Sep-Oct; 14(5): 387-93.
  7. Quigley HA: Identification of glaucoma-related visual field abnormality with the screening protocol of frequency doubling technology; Am J Ophthalmol; 1998 June, 125(6): 819-29.
  8. Robin TA, Müller A, Rait J, et al. Performance of community-based glaucoma screening using Frequency Doubling Technology and Heidelberg Retinal  omography. Ophthalmic Epidemiol. 2005 June; 12(3): 167-78.
  9. Iwase A et al. Performance of frequency-doubling technology perimetry in a population-based prevalence survey of glaucoma: the Tajimi study. Ophthalmology. 2007 Jan;  114(1): 27-32. Epub 2006 Oct 27.
  10. Saito M, Yamashiro H, Matsumoto H, Shirato S. [Usefulness of frequency doubling technology as a screening test for glaucoma] [Article in Japanese] Nippon  Ganka Gakkai Zasshi. 2001 Jan; 105(1): 20-3.
  11. Kusaba K, Kawanami M, Ban Y. [The usefulness of frequency doubling technology perimetry in glaucoma screening in health-check program]. [Article in Japanese] Nippon Ganka Gakkai Zasshi. 2004 Sep; 108(9): 554-9.
  12. Tatemichi M, Nakano T, Tanaka K, et al. Performance of glaucoma mass screening with only a visual field test using frequency-doubling technology perimetry. Am J Ophthalmol; 2002 Oct; 134(4): 529-37. Erratum in: 2003 Sep; 136(3): 592.
  13. Jonas JB, Xu L, Wang YX, et al. The Beijing Eye Study. Acta Ophthalmol. 2009 May; 87(3): 247-61.
  14. Thomas R, Naveen S, Nirmalan P, Parikh R. Detection of Ocular Disease by a Vision Center Technician & The Role of Frequency Doubling Technology Perimetry in this Setting. Br J Ophthalmol. 2009 Aug 18: [Epub ahead of print].
  15. Wang Y, Xu L, and Jonas JB. Prevalence and causes of visual field loss as determined by frequency doubling perimetry in urban and rural adult Chinese. Am J Ophthalmol, 2006 Jun; 141(6): 1078-1086.

SAP# 000000-1781-970 FDT .2415 0909
The contents of the brochure may differ from the current status of approval of the product in your country. Please contact your regional representative for more
information. Subject to change in design and scope of delivery and as a result of ongoing technical development. © 2009 by Carl Zeiss Meditec, Inc. All copyrights reserved. Cirrus HD-OCT, Humphrey, Humphrey FDT and IOLMaster are either registered trademarks or trademarks of Carl Zeiss Meditec, Inc. in the United States and/or other countries. Printed in XXXX XM

Carl Zeiss Meditec, Inc.
5160 Hacienda Drive
Dublin, CA 94568

Phone: +1 925 557 4100
Toll free: 1 800 342 9821
+1 925 557 4101
[email protected]

Carl Zeiss Meditec AG
Goeschwitzer Str. 51-52
07745 Jena

Phone: +49 36 41 22 03 33
Fax: +49 36 41 22 01 12
[email protected]